Global Hospital-Acquired Infection Treatment Market Report and Forecast 2024-2032

Global Hospital-Acquired Infection Treatment Market Outlook

The hospital-acquired infection treatment market size was estimated to be worth USD 15.95 billion in 2023. The market is expected to rise at a growth rate of 4.5% in the forecast period of 2024-2032 to attain a market size of nearly USD 23.66 billion by 2032. Novel therapy launches and approvals are expected to fuel the market growth during the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Hospital-Acquired Infection: Type, Causes, Diagnosis, and Treatment

Hospital-acquired infection are infections that are acquired by the hospital or any other healthcare facility or from any healthcare professional, including doctors and nurses, among others, during the course of the treatment. The hospital-acquired infection are also referred to as healthcare-associated infections and nosocomial infections.

There are different types of healthcare-associated infections depending on the mode of entry of the causative pathogen and the type of the pathogen. According to the Centers for Disease Control and Prevention, nearly 1.7 million healthcare-associated infections were reported in the United States.

There are several modes of transmission attributing to the widespread of hospital-acquired infection, such as contact transmission, droplet transmission, airborne transmission, common vehicle transmission, and vector-borne transmission.

Nosocomial infections can be prevented by following several preventative steps and measures including sanitation, sterilisation, isolation, and frequent sanitation habits. The treatment for these types of infections is solely based on the eradication of the causative agents, responsible for causing the disease.

There are different antibiotics approved for eradicating or slowing the growth of the gram-positive strains of Staphylococcus aureus and gram-negative strains of Acinetobacter baumannii. Several other novel therapeutic medications are under clinical development for providing better therapeutic and diagnostic care.

According to the hospital-acquired infection treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Product and Services

• Sterilization
  • Sterilization Products
    • Heat Sterilization Equipment
    • Low-Temperature Sterilization Equipment
    • Radiation Sterilization Equipment
    • Other Sterilization Equipment
  • Contract Sterilization Services
  • Sterilization Consumables and Accessories
• Cleaning and Disinfection Products
  • Disinfectants
  • Disinfectors Equipment
  • Others
• Protective Barriers

• Endoscope Reprocessing Products

Market Breakup by Infection Type

• Hospital-acquired Pneumonia

• Bloodstream Infections

• Surgical Site Infections

• Gastrointestinal Infections

• Urinary Tract Infections (UTIs)

• Others

Market Breakup by Application

• Drug-Resistance Testing

• Disease Testing

• Others

Market Breakup by End User

• Hospitals and ICUs

• Ambulatory Surgical and Diagnostic Centres

• Nursing Homes and Maternity Centres

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The growth of the hospital-acquired infection treatment market is primarily driven by the rising incidence and prevalence of healthcare-associated infections. This is further stimulated by the growing cases of chronic disorders and surgeries, which require prolonged hospital stays and thus will increase the risk of acquiring nosocomial infections. Additionally, the technological advancements in the devices implemented for infection control are also expected to bolster the market growth during the forecast period.

The hospital-acquired infection treatment market is augmented by the higher rate of surgical site infections, which is anticipated to increase the demand for the products and devices to manage hospital-acquired infection, and henceforth propel the market growth. According to the Centers for Disease Control and Prevention, nearly 20,000 surgical site infections were reported in the United States, thus accounting for significant market growth.

With extensive research and innovation, there is the discovery of novel therapeutic products by the key players and the major pharmaceutical companies. For example, Esco discovered a new sterilization device, incorporating a Cell Culture CO2 Incubator with High Heat Sterilization (CCL-HHS). The discovery of these devices will aid the eradication of the microorganisms contaminating the marketplace. Such product launches and approvals are expected to boost the market expansion in the forthcoming period.

Among the products segment, the disinfectants segment is anticipated to dominate the hospital-acquired infection treatment market owing to the increasing prevalence of chronic disorders, hospital-acquired infection, rising awareness, and the growing number of surgical interventions. Several reports suggested that nearly half of nosocomial infections occur in the intensive care units. The application of surface disinfectants aid in the prevention of these infections and will boost the market growth.

North America Accounts for the Largest Share

North America is anticipated to account for the largest share of the hospital-acquired infection treatment market due to the growth in hospital stays with the increase in the number of chronic diseases and surgeries. This can be attributed to the rising number of hospital admissions, that too for an extended period. Further, this will also increase the chances of hospital-acquired infection and will bolster the market development.

Therapeutic Landscape

The hospital-acquired infection are generally treated with the help of medications and other home remedies. The diagnosis of the infection is performed using the help of blood tests, X-rays, and other diagnostic tests based on the symptoms. 

Antibiotics are the most prescribed medications used for the treatment of nosocomial infections. The antibiotics act against the bacteria responsible for causing the infections by killing them or slowing their growth. 

The two bacteria species that are likely to infect patients are Gram-positive strains of Staphylococcus aureus and Gram-negative strains of Acinetobacter baumannii. The frequent hospital-acquired infection are of the surgical site, urinary tract, and several types of pneumonia. An alternative treatment strategy used for the management of these infections is irradiation incorporating ultraviolet C.

In case the infection is caused by any foreign device such as a catheter, the doctor may remove it for the appropriate medical period. Home remedies such as the administration of a balanced diet, high fluid intake, and proper rest are the additional treatment measures that will assist in faster and better recovery.

Clinical Trials Landscape

With the increasing prevalence of chronic disorders, the risk of hospital-acquired infection also increases. For better diagnosis and treatment, clinical researchers and scientists are working on discovering novel therapeutic interventions that will aid in the management of non-cosmical infections.

Vir Biotechnology, a key market player, is evaluating the potential of its new therapies, VIR-3434 and VIR-2218, that could be considered as a functional cure for chronic hepatitis virus infection. This type of infection is categorised as healthcare-associated, and if successfully passed, it will help in bolstering the growth of the hospital-acquired infection treatment market.

Ascentage Pharma, another major pharmaceutical company, is performing clinical trials for the novel drug, which is anticipated to act by inhibiting the apoptosis protein antagonist in Chinese patients suffering from chronic hepatitis virus, which can be acquired from hospitals and other medical centres.

With time, the bacterial strains develop microbial resistance against the available antibiotics, thus the scientists are working on developing novel treatment options for managing resistant pneumonia. The newer treatment methods and faster approvals by the regulatory authorities are expected to boost the hospital-acquired infection treatment market growth during the forecast period.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the hospital-acquired infection treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• 3M

• Belimed AG

• Ecolab Inc.

• Fortive

• Getinge AB

• Bayer AG

• Danaher

• Novartis AG

• Merck & Co., Inc.

• Abbott

• Pfizer Inc.

Key Highlights of the Report